Please login to the form below

Not currently logged in
Email:
Password:

opicapone

This page shows the latest opicapone news and features for those working in and with pharma, biotech and healthcare.

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine bags FDA approval for first tardive dyskinesia drug

The company fleshed out its movement disorder pipeline earlier this year by licensing opicapone from Portuguese drug maker BIAL.

Latest news

  • EC approves Bial’s Parkinson’s disease therapy EC approves Bial’s Parkinson’s disease therapy

    Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adults with Parkinson's and end-of-dose motor fluctuations who cannot ... Opicapone is a third-generation

  • Chasing the cure for Parkinson's disease Chasing the cure for Parkinson's disease

    Opicapone (Bial) is a COMT inhibitor in phase III development in various European countries for the treatment of idiopathic Parkinson's. ... Bial plans to develop opicapone to be administered in combination with levodopa/carbidopa or

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics